HK Stock Market Move | ASIAINFO TECH (01675) rose more than 7% after its performance, with explosive growth in the application and delivery of AI large models. The company expects its full-year profit to exceed that of the previous year.
ASIATECH (01675) rose more than 7% after its performance, up 7.13% to HKD 11.87 by the time of publication, with a turnover of HKD 2.11 billion.
ASIAINFO TECH (01675) rose more than 7% after the performance report, reaching 7.13% as of press time, at HK$11.87, with a turnover of HK$2.11 billion.
On the news front, ASIAINFO TECH announced its mid-year performance, with operating income of about 25.98 billion yuan. Of this, ICT support business income is about 21.18 billion yuan; digital operation business income is about 4.08 billion yuan; 5G private network and application business income is about 0.47 billion yuan, with orders in the first half of the year of about 0.82 billion yuan, a year-on-year increase of 51.7%; AI large model application and delivery business achieved explosive growth, with business income of about 0.26 billion yuan, a year-on-year increase of 76 times, and orders in the first half of the year of about 0.7 billion yuan, a year-on-year increase of 78 times.
The announcement stated that, in response to the transformation challenges of the ICT support business, the company has actively implemented measures, such as using AI tools to improve efficiency, strengthening centralized procurement, building a one-stop public consumption platform, optimizing personnel structure, and a series of cost reduction and efficiency enhancement measures. Cost control has been effective. The company's gross profit in the first half of the year was about 7.83 billion yuan, an increase of 6.1% year-on-year; gross profit margin was 30.1%, up 5.4 percentage points year-on-year. Operating cash flow improvement improved by 35.3% year-on-year. Excluding one-time severance compensation for personnel structure optimization, the net loss for the period was about 0.48 billion yuan, compared to a net loss of about 0.7 billion yuan in the same period last year. The company expects net profit in the second half of the year to continue to rise, with profits expected to exceed last year's.
Related Articles

Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) passed the drug cGMP on-site inspection.

BP p.l.c. Sponsored ADR (BP.US) exceeded earnings expectations in Q2. The new chairman will lead reforms and launch a comprehensive review of the business.

HK Stock Market Move | JUNSHI BIO (01877) rose nearly 35% in the final trading session. The company had previously raised over 1 billion for research and development of PD-1/VEGF bispecific antibodies, among other projects.
Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) passed the drug cGMP on-site inspection.

BP p.l.c. Sponsored ADR (BP.US) exceeded earnings expectations in Q2. The new chairman will lead reforms and launch a comprehensive review of the business.

HK Stock Market Move | JUNSHI BIO (01877) rose nearly 35% in the final trading session. The company had previously raised over 1 billion for research and development of PD-1/VEGF bispecific antibodies, among other projects.

RECOMMEND

EU Defers Two Retaliatory Measures Against U.S. Tariffs by Six Months to Facilitate Trade Negotiations
05/08/2025

July Special Bond Issuance Reaches Year-to-Date Peak, Poised to Reinforce Infrastructure Investment
05/08/2025

Inbound Tourism Accelerates as China’s Travel Service Exports Jump Nearly 70% in H1
05/08/2025